By Fineline Cube AstraZeneca plc (NYSE: AZN) announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit-risk profile for its Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for treating patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC).
Regulatory Status & Timeline
| Milestone | Date |
|---|---|
| sNDA Acceptance | August 2025 |
| ODAC Meeting & Recommendation | 30 April 2026 |
| PDUFA Decision Date | Not yet disclosed |
| Current Indication | HR-positive, HER2-negative breast cancer with PIK3CA/AKT1/PTEN alterations |
The supplemental New Drug Application (sNDA) seeking this new indication was accepted by the FDA in August 2025, with the recent ODAC recommendation representing a significant step toward potential approval.
Drug Profile & Mechanism of Action
- Molecule: First-in-class, potent, adenosine triphosphate (ATP)-competitive AKT inhibitor
- Target: All three AKT isoforms (AKT1/2/3)
- Current Approval: In combination with Faslodex (fulvestrant) for HR-positive, HER2-negative locally advanced or metastatic breast cancer with biomarker alterations (PIK3CA, AKT1, or PTEN)
- Proposed New Indication: PTEN-deficient mHSPC in combination with abiraterone and ADT
Clinical Evidence – CAPItello-281 Phase 3 Trial
| Endpoint | Truqap + Abiraterone/ADT | Placebo + Abiraterone/ADT | Benefit |
|---|---|---|---|
| Risk Reduction (rPFS/Death) | – | – | 19% statistically significant reduction |
| Median rPFS Improvement | +7.5 months | Reference | Clinically meaningful benefit |
| Patient Population | PTEN-deficient mHSPC | PTEN-deficient mHSPC | Biomarker-selected cohort |
The CAPItello-281 trial demonstrated that the addition of Truqap to standard abiraterone and ADT therapy resulted in a statistically significant 19% reduction in the risk of radiographic disease progression or death, along with a clinically meaningful 7.5-month improvement in median radiographic progression-free survival (rPFS).
Market Impact & Strategic Outlook
- Prostate Cancer Market: Global mHSPC market estimated at $8-10 billion annually, with limited targeted therapy options for biomarker-defined subpopulations
- Competitive Differentiation: Truqap represents one of the first precision medicine approaches specifically for PTEN-deficient prostate cancer
- Commercial Strategy: Leverages existing Truqap commercial infrastructure established for breast cancer indication
- Biomarker Testing: Expected to drive adoption of PTEN testing in prostate cancer, creating diagnostic partnership opportunities
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for Truqap. Actual results may differ due to risks including final FDA approval decisions, market adoption, and competitive dynamics.-Fineline Info & Tech